Failure to protect the myocardium against ischemia/reperfusion injury after chronic atorvastatin treatment is recaptured by acute atorvastatin treatment: A potential role for phosphatase and tensin homolog deleted on chromosome ten?

Journal of the American College of Cardiology

Volumn 45, Issue 8, 2005, Pages 1287-1291

  Mensah, Kwabena ^a   Mocanu, Mihaela M ^a   Yellon, Derek M ^a,b  

^a UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHROMOSOME 10; CHROMOSOME DELETION; CONTROLLED STUDY; DOSE RESPONSE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEART PROTECTION; LONG TERM CARE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; REPERFUSION INJURY; TISSUE LEVEL; TREATMENT OUTCOME;

EID: 17144405293     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2005.01.021     Document Type: Article

References (42)

1. J.L. Goldstein, M.S. Brown Regulation of the mevalonate pathway Nature 343 1990 425 430
2. J. Shepherd, S.M. Cobbe, I. Ford West of Scotland Coronary Prevention Study Group Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia N Engl J Med 333 1995 1301 1307
3. Scandinavian Simvastatin Survival Study Group Randomised trial of cholesterol lowering in 4,444 patients with coronary heart disease the Scandinavian Simvastatin Survival Study (4S) Lancet 344 1994 1383 1389
4. F.M. Sacks, M.A. Pfeffer, L.A. Moye Cholesterol and Recurrent Events Trial Investigators The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels N Engl J Med 335 1996 1001 1009
5. B. Pitt, D. Waters, W.V. Brown Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators N Engl J Med 341 1999 70 76
6. Y. Kureishi, Z. Luo, I. Shiojima The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals Nat Med 6 2000 1004 1010
7. H. Tong, W. Chen, C. Steenbergen Ischemic preconditioning activates phosphatidylinositol-3-kinase upstream of protein kinase C Circ Res 87 2000 309 315
8. D.J. Hausenloy, M.M. Mocanu, D.M. Yellon Ischemic preconditioning protects by activating pro-survival kinases at reperfusion Am J Physiol Heart Circ Physiol 288 2005 H971 H976
9. S.P. Jones, S.D. Trocha, D.J. Lefer Pretreatment with simvastatin attenuates myocardial dysfunction after ischemia and chronic reperfusion Arterioscler Thromb Vasc Biol 21 2001 2059 2064
10. R.M. Bell, D.M. Yellon Atorvastatin, administered at the onset of reperfusion, and independent of lipid lowering, protects the myocardium by up-regulating a pro-survival pathway J Am Coll Cardiol 41 2003 508 515
11. P. Di Napoli, T.A. Antonio, A. Grilli Simvastatin reduces reperfusion injury by modulating nitric oxide synthase expression an ex vivo study in isolated working rat hearts Cardiovasc Res 51 2001 283 293
12. A.M. Lefer, B. Campbell, Y.K. Shin Simvastatin preserves the ischemic-reperfused myocardium in normocholesterolemic rat hearts Circulation 100 1999 178 184
13. K. Ichihara, K. Satoh, A. Yamamoto [Are all HMG-CoA reductase inhibitors protective against ischemic heart disease?] Nippon Yakurigaku Zasshi 114 Suppl 1 1999 142P 149P
14. K. Ichihara, K. Satoh, Y. Abiko Influences of pravastatin and simvastatin, HMG-CoA reductase inhibitors, on myocardial stunning in dogs J Cardiovasc Pharmacol 22 1993 852 856
15. S.R. Datta, H. Dudek, X. Tao Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery Cell 91 1997 231 241
16. A. Brunet, A. Bonni, M.J. Zigmond Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor Cell 96 1999 857 868
17. S.R. Datta, A. Brunet, M.E. Greenberg Cellular survival a play in three Akts Genes Dev 13 1999 2905 2927
18. T. Matsui, L. Li, J.C. Wu Phenotypic spectrum caused by transgenic overexpression of activated Akt in the heart J Biol Chem 277 2002 22896 22901
19. M.V. Latronico, S. Costinean, M.L. Lavitrano Regulation of cell size and contractile function by AKT in cardiomyocytes Ann N Y Acad Sci 1015 2004 250 260
20. M.A. Crackower, G.Y. Oudit, I. Kozieradzki Regulation of myocardial contractility and cell size by distinct PI3K-PTEN signaling pathways Cell 110 2002 737 749
21. H.G. Wendel, E. De Stanchina, J.S. Fridman Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy Nature 428 2004 332 337
22. M. Sun, G. Wang, J.E. Paciga AKT1/PKBalpha kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells Am J Pathol 159 2001 431 437
23. Y. Li, K. Podsypanina, X. Liu Deficiency of PTEN accelerates mammary oncogenesis in MMTV-Wnt-1 transgenic mice BMC Mol Biol 2 2001 2
24. G.Y. Oudit, H. Sun, B.G. Kerfant, M.A. Crackower, J.M. Penninger, P.H. Backx The role of phosphoinositide-3 kinase and PTEN in cardiovascular physiology and disease J Mol Cell Cardiol 37 2004 449 471
25. G.G. Schwartz, A.G. Olsson, M.D. Ezekowitz Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial JAMA 285 2001 1711 1718
26. J.R. Downs, M. Clearfield, S. Weis Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study JAMA 279 1998 1615 1622
27. M. Essig, F. Vrtovsnik, G. Friedlander [Inhibitors of HMG CoA reductase new modes of action, new indications?] Therapie 55 2000 43 49
28. U. Laufs, K. Gertz, U. Dirnagl Rosuvastatin, a new HMG-CoA reductase inhibitor, upregulates endothelial nitric oxide synthase and protects from ischemic stroke in mice Brain Res 942 2002 23 30
29. U. Laufs, J.K. Liao Direct vascular effects of HMG-CoA reductase inhibitors Trends Cardiovasc Med 10 2000 143 148
30. S.I. McFarlane, R. Muniyappa, R. Francisco Clinical review 145: pleiotropic effects of statins: lipid reduction and beyond J Clin Endocrinol Metab 87 2002 1451 1458
31. N.S. Wayman, B.L. Ellis, C. Thiemermann Simvastatin reduces infarct size in a model of acute myocardial ischemia and reperfusion in the rat Med Sci Monit 9 2003 BR155 BR159
32. Y. Kureishi, Z. Luo, I. Shiojima The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals Nat Med 6 2000 1004 1010
33. S. Dimmeler, A. Aicher, M. Vasa HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway J Clin Invest 108 2001 391 397
34. M.M. Mocanu, R.M. Bell, D.M. Yellon PI3 kinase and not p42/p44 appears to be implicated in the protection conferred by ischemic preconditioning J Mol Cell Cardiol 34 2002 661 668
35. D.J. Hausenloy, D.M. Yellon New directions for protecting the heart against ischaemia-reperfusion injury targeting the Reperfusion Injury Salvage Kinase (RISK)-pathway (review) Cardiovasc Res 61 2004 448 460
36. D.J. Hausenloy, M.M. Mocanu, D.M. Yellon Cross-talk between the survival kinases during early reperfusion its contribution to ischemic preconditioning Cardiovasc Res 63 2004 305 312
37. O.I. Pisarenko, I.M. Studneva, V.Z. Lankin Inhibitor of beta-hydroxy-beta-methylglutaryl coenzyme A reductase decreases energy supply to the myocardium in rats Bull Exp Biol Med 1 2001 956 958
38. K. Satoh, K. Ichihara Lipophilic HMG-CoA reductase inhibitors increase myocardial stunning in dogs J Cardiovasc Pharmacol 35 2000 256 262
39. M.L. Sulis, R. Parsons PTEN from pathology to biology Trends Cell Biol 13 2003 478 483
40. L.M. Sly, M.J. Rauh, J. Kalesnikoff, T. Buchse, G. Krystal SHIP, SHIP2, and PTEN activities are regulated in vivo by modulation of their protein levels SHIP is up-regulated in macrophages and mast cells by lipopolysaccharide Exp Hematol 31 2003 1170 1181
41. C. Weinbrenner, C.P. Baines, G.-S. Liu Fostriecin, an inhibitor of protein phosphatase 2A, limits myocardial infarct size even when administered after onset of ischemia Circulation 98 1998 899 905
42. Q. Cai, G.F. Baxter, D.M. Yellon Reduction of infarct size in isolated rat heart by CsA and FK506 possible role of phosphatase inhibition Cardiovasc Drugs Ther 12 1998 499 501